TY - JOUR
T1 - Adjunctive raloxifene for postmenopausal women with schizophrenia
T2 - A meta-analysis of randomized, double-blind, placebo-controlled trials
AU - Zhu, Xiao Min
AU - Zheng, Wei
AU - Li, Xiao Hong
AU - Cai, Dong Bin
AU - Yang, Xin Hu
AU - Ungvari, Gabor S.
AU - Ng, Chee H.
AU - Wang, Xiao Ping
AU - Kulkarni, Jayashri
AU - Grigg, Jasmin
AU - Ning, Yu Ping
AU - Xiang, Yu Tao
PY - 2018/7/1
Y1 - 2018/7/1
N2 - Objective: Raloxifene, a selective estrogen receptor modulator, has been used in treating postmenopausal women with schizophrenia with inconsistent results. This meta-analysis of randomized, double-blind, placebo-controlled trials (RCTs) examined its efficacy and safety for postmenopausal women with schizophrenia. Method: Standardized mean differences (SMDs) and risk ratio (RR) together with their 95% confidence intervals (CIs) were calculated using the random effects model. Results: The meta-analysis included 5 RCTs (n = 240) comparing raloxifene (n = 125, 60 or 120 mg/day) with placebo (n = 115). Adjunctive raloxifene outperformed placebo with regard to the Positive and Negative Syndrome Scale (PANSS) total psychopathology [n = 240, SMD:-0.64 (95%CI:-0.90, −0.37), P < 0.00001; I2 = 0%], positive symptoms [n = 240, SMD:-0.49 (95%CI:-0.81, −0.16), P = 0.003; I2 = 29%], negative symptoms [n = 240, SMD:-0.43 (95%CI:-0.68, −0.17), P = 0.001; I2 = 0%], and general psychopathology scores [n = 240, SMD:-0.66 (95%CI:-0.92, −0.39), P < 0.00001; I2 = 0%]. Both groups had similar rates of adverse events and discontinuation (n = 159, RR: 1.32 (95%CI: 0.65, 2.70), P = 0.44, I2 = 0%). Conclusion: Adjunctive raloxifene appears to be effective and safe in improving psychotic symptoms for postmenopausal women with schizophrenia. Review registration: CRD 42017059946
AB - Objective: Raloxifene, a selective estrogen receptor modulator, has been used in treating postmenopausal women with schizophrenia with inconsistent results. This meta-analysis of randomized, double-blind, placebo-controlled trials (RCTs) examined its efficacy and safety for postmenopausal women with schizophrenia. Method: Standardized mean differences (SMDs) and risk ratio (RR) together with their 95% confidence intervals (CIs) were calculated using the random effects model. Results: The meta-analysis included 5 RCTs (n = 240) comparing raloxifene (n = 125, 60 or 120 mg/day) with placebo (n = 115). Adjunctive raloxifene outperformed placebo with regard to the Positive and Negative Syndrome Scale (PANSS) total psychopathology [n = 240, SMD:-0.64 (95%CI:-0.90, −0.37), P < 0.00001; I2 = 0%], positive symptoms [n = 240, SMD:-0.49 (95%CI:-0.81, −0.16), P = 0.003; I2 = 29%], negative symptoms [n = 240, SMD:-0.43 (95%CI:-0.68, −0.17), P = 0.001; I2 = 0%], and general psychopathology scores [n = 240, SMD:-0.66 (95%CI:-0.92, −0.39), P < 0.00001; I2 = 0%]. Both groups had similar rates of adverse events and discontinuation (n = 159, RR: 1.32 (95%CI: 0.65, 2.70), P = 0.44, I2 = 0%). Conclusion: Adjunctive raloxifene appears to be effective and safe in improving psychotic symptoms for postmenopausal women with schizophrenia. Review registration: CRD 42017059946
KW - Meta-analysis
KW - Postmenopause
KW - Raloxifene
KW - Schizophrenia
KW - Women
UR - http://www.scopus.com/inward/record.url?scp=85040771095&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2018.01.017
DO - 10.1016/j.schres.2018.01.017
M3 - Article
AN - SCOPUS:85040771095
SN - 0920-9964
VL - 197
SP - 288
EP - 293
JO - Schizophrenia Research
JF - Schizophrenia Research
ER -
